Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
By Gregg Stone, J. Moses, S. Ellis, J. Schofer, K. Dawkins, M. Morice, A. Colombo, E. Schampaert, E. Grube, A. Kirtane and 5 more. New England Journal of Medicine, 2007
1,696 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/4ffd342860a15359e0fabe7afa06ead4ebc580ec
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- S. Garg
- Patrick W. Serruys
- R. Motterlini
- David F. Williams
- S. King
- L. Otterbein
- F. Feres
- M. Midei
Citations in the corpus
- The therapeutic potential of carbon monoxide (2010, background): “Coated stents are designed to release agents such as rapamycin to block vascular smooth muscle cell proliferation, but a striking drawback is that they limit re-endothelialization, which leads to thrombosis, inflammation and restenosi”
- Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. (2008, background): “Importantly, there were no significant differences in the occurrence of stent thrombosis through 1 year between these 2 devices, though this trial was underpowered to reliably evaluate this event; also, longer-term follow-up is required, because the incremental risk of stent thrombosis with drug-elu”
- Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. (2013, methodology): “The perprotocol population was defined as intention-to-treat patients with (1) successful procedure outcome, (2) treatment solely with the zotarolimus-eluting stent, (3) dual antiplatelet therapy according to randomization, and (4) complete clinical follow-up information.”
- On the nature of biomaterials. (2009, background): “[36] with per re-stenosis clinically [33], but have also resulted in higher levels of the far more damaging thrombo-embolic events [34].”
- Coronary stents: current status. (2010, positive): “In addition, patient-level metanalysis of the initial PES approval trials has confirmed the omparable safety and superior efficacy of PES compared with MS out to 4-year follow-up (Table 3) (22,24).”